KIT and neoplasm: Since imatinib preferentially targets mutant receptors [6], reduced drug responsiveness [9,10] and aggressive GIST behavior [11] may also reflect activation of WT KIT expressed in the majority of GIST by KITLG originating from the circulation, the tumor cells, or their niche [9,11-13].